HER-2/neu Peptide Vaccine
DRACPC ID DRACPC0098
Active Ingredients HER-2/neu Peptide Vaccine
Description A cancer vaccine comprised of peptides derived from the extracellular domain of the tumor-associated antigen Her-2/neu with potential antineoplastic activity. HER-2/neu peptide vaccine may induce antibodies with anti-tumor activity and may also elicit a specific CD8 T-cell response against specific tumor cell types.
Synonyms HER-2/neu Helper-Peptide Vaccine; HER-2-Neu Peptide Vaccine; HER-2/neu Peptide Vaccine
Type Biotech
Disease Stage IV Breast Cancer, Stage IV Ovarian Cancer
Classification
Peptide and derivative
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence Not available
Sequence Length Not available
Modification Not available
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C2537
UNII Not available
CAS Not available
Drug approval
Drug indication
Investigated for use/treatment in Stage IV Breast Cancer, Stage IV Ovarian Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00194714 | Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo | HER2/Neu Positive; HLA-A2 Positive Cells Present; Stage IV Breast Cancer; Stage IV Ovarian Cancer | Phase 1/2 | Treatment |
| NCT00068614 | A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer | Breast Cancer | Phase 1 | Treatment |
| NCT00005023 | A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers | Breast Cancer; Lung Cancer; Ovarian Cancer | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
